Sign in

    Jordyn Fantuzzi

    former Research Analyst at Piper Sandler

    Jordyn Fantuzzi is a former Research Analyst at Piper Sandler & Co., where she specialized in equity research with sector exposure related to biotechnology and healthcare. During her tenure from 2016 to 2020, she notably covered companies such as Marker Therapeutics, actively participating in earnings calls and contributing to analytical discussions. Fantuzzi earned her undergraduate degree from New York University and built early career experience as an Assistant Wine Analyst at City Winery LLC before moving into financial services. Her professional background is complemented by substantial industry engagement, although publicly available records do not specify FINRA licenses or widely recognized investment performance metrics.

    Jordyn Fantuzzi's questions to Marker Therapeutics (MRKR) leadership

    Jordyn Fantuzzi's questions to Marker Therapeutics (MRKR) leadership • Q1 2020

    Question

    Jordyn Fantuzzi, on for Ed at Piper Sandler, asked about the commitment shares under the Aspire Capital purchase agreement, questioning the price per share and if the potential capital was included in the company's reported cash position for the quarter.

    Answer

    CFO Tony Kim explained that the company has not yet drawn down any capital from the Aspire agreement and that the current cash balance of $40.3 million does not necessitate an immediate draw. President and CEO Peter Hoang added that the potential funds from the Aspire facility are not reflected in the company's cash runway guidance, which is based on cash on hand.

    Ask Fintool Equity Research AI